Stocks’ Details and Price Movements
 

Dotz Nano Limited (ASX: DTZ)

Launchedan Effective Tracing Solution at a Customer Fracking Site - Dotz, is a strong, established distributor in North America, Europe, Japan, China and Australia.  It is a technology leader in research, production and marketing of anti-counterfeiting, authentication and tracing solutions. Dotz achieved a major step towards commercialization of its ground-breaking technology. DTZ’s tracing technology, Fluorensic™, was proved to be an economical and an effective one as it provided immediate on-site results. The technology along with its detection solution provided accurate data in real time without having to wait days for lab testing. In June 2018, a field trial was held with a Payne County, Tulsa Oklahoma (USA) based international specialty chemical supplier of frac chemicals and two types of Fluorensic™ tracers were tested. The field trial was declared successful after withstanding extreme pressure and temperatures conditions. Moreover, Dotz was able to demonstrate its on-site on-line detection capability. Dotz Nano also announced that it has terminated its agreement with the Company's previous corporate advisor Otsana Capital. After a successful pilot in 2018 with a known oil company for Tagging and Tracing of Frac Fluids, other oil companies are now in the process of implementing Dotz’s Fluorensic™. The stock surged up by 16 per cent as on 26 June 2018. We recommend to “Hold” the stock at the current market price of $0.087 as the Company is focusing on commercialization by targeting mature markets while the stock was under pressure for quite some time (down 55.88% in last one year).
 

Focus Areas of the Company (Source: Company Reports)
 

Northern Cobalt Limited (ASX: N27)

Disappointment with the portable XRF which was to be used for rapid turnaround - Northern Cobalt released an update related to its drilling while it had planned to use a portable XRF for rapid turnaround and re-targeting, the unit has been returned to the manufacturer for repairs. From that time onwards, the Group has been testing its drilling targets consisting of magnetic lows similar to that underlying the Stanton Cobalt Deposit. This planned field work at the Wollogorang Project will be a large continuous program that will be set to run until the end of the year and in the meantime, the Company will focus on adding resource tonnes near the existing Stanton Cobalt Deposit. This program will include certain operations like drill testing multiple targets with aircore, slimline hammer and RC drilling within a 40km radius of Stanton, drill testing of the Karns and Selby satellite prospects with diamond drilling expected in 2H 2018 and other relevant activities. 50 per cent of the drilling got completed at Wollogorang Project at average depth of 5m and samples were sent to laboratory. Some operational issues were reported with the portable XRF which resulted in delays of the drilling result. It is planning to extend aircore program with new zones of interest from geophysics. The stock fell by 23.256 per cent on 26 June 2018. We maintain the “Hold” recommendation on the stock at the current market price of $0.165 by looking at the commodity price landscape while the Company has already started working to resolve the issues with portable XRF which it will use for better results.


Image of Wollogorang Project (Source: Company Reports)
 

Dorsavi Limited (ASX: DVL)

Launch of an Innovative Product to enhance market penetration - DVL announced the commercial launch of its new product, dorsaVi Professional Suite, in the United States, with the first set of pre-orders shipping. This will allow clinicians, such as running specialists and physical therapists, to access the latest generation dorsaVi technology which is simple to use, mobile and cost effective. As Company plans to grow annuity revenue, dorsaVi Professional Suite adopts a SaaS model that is users will pay for the hardware and will need to pay an ongoing monthly fee for access to the software licence.  This user-friendly interface means that it can be used by a range of health professionals, such as physical therapists, strength and conditioning trainers, running coaches, chiropractors and podiatrists. Further, the technology can also be used by orthopaedic specialists to track patient progress and by pharmaceutical companies to validate clinical claims in relation to improvements in patient activity. The Company received its first pre-order shipment of the Professional Suite which is a step towards capturing the interest in the market. The group launched ViMove2 in Australia in May 2017 and intends to launch in the UK in the second quarter of FY18. The group is planning a smooth launch into the U.S., which is a major clinical market while the group has a solid level of customer satisfaction in theU.S. clinical market. The stock moved up by 9.09 per cent and closed at $0.12 on June 26, 2018. We give a “Hold” recommendation as it will be better to wait and watch the impact of the launch of this new product in the market.


Customer Revenue Trend (Source: Company Reports)

 
Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.